Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Emerson Electric Co. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.7 (market cap $39.89B), while Emerson Electric Co. trades at $137.27 (market cap $77.79B). The key difference: Emerson Electric Co. is the larger of the two by market cap, and Emerson Electric Co. pays a 1.6% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EMR | |
|---|---|---|
Market Cap | $39.89B | $77.79B |
Sector | Health | Industrials |
52-Week High | $491.22 | $161.69 |
52-Week Low | $278.09 | $123.30 |
Enterprise Value | $38.15B | $90.05B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Emerson Electric (EMR) trades at $138.88, up 0.78% today, with a bearish technical signal from moving averages. The stock shows stable revenue growth, with 2025 revenue of $18.02B and net income of $2.29B, supported by a strong gross profit margin of 52.67%. Recent news highlights investor attention and collaboration with Aramco on corrosion R&D, while the Intelligent Devices segment gains momentum.
EMR presents a mixed outlook: analyst consensus is bullish with a $157.60 price target, but technical indicators suggest near-term pressure. Key risks include volatile cash flows and competitive pressures in manufacturing electronics. The stock's valuation at a P/E of 32.15 may limit upside unless earnings accelerate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
